Background <p>Colorectal carcinoma exhibits high heterogeneity, comprising subtypes that show poor efficacy of T cell-based immunotherapies, such as programmed cell death protein 1 (PD-1) checkpoint inhibitors. Although natural killer (NK) cells are considered a promising approach for cancer immunotherapy, it remains unclear what molecular mechanisms drive NK cell activation or suppression within the tumor microenvironment. Moreover, limitations in human tumor…
Colorectal cancer organoids drive hypoxia, TGF-{beta}, and patient-specific diversification of NK cell activation programs
Journal for ImmunoTherapy of Cancer | | von Kries, A., Garces-Lazaro, I., Balzasch, B. M., Sticht, C., Shaltiel, I. A., Boonekamp, K. E., Sams, A., Triassi, A., Hofman, T., Burgermeister, E., Betge, J., Ebert, M., Boutros, M., Helming, L., Stojanovic, A., Cerwenka, A.
Topics: colorectal-cancer, skin-cancer, cervical-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer